产品名称
吡拉西坦, European Pharmacopoeia (EP) Reference Standard
InChI
1S/C6H10N2O2/c7-5(9)4-8-3-1-2-6(8)10/h1-4H2,(H2,7,9)
SMILES string
NC(=O)CN1CCCC1=O
InChI key
GMZVRMREEHBGGF-UHFFFAOYSA-N
grade
pharmaceutical primary standard
API family
piracetam
manufacturer/tradename
EDQM
application(s)
pharmaceutical (small molecule)
format
neat
storage temp.
2-8°C
正在寻找类似产品? 访问 产品对比指南
Application
Piracetam EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Other Notes
Sales restrictions may apply.
Packaging
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
存储类别
11 - Combustible Solids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
A A Al Hajeri et al.
The Cochrane database of systematic reviews, (2)(2), CD006111-CD006111 (2007-04-20)
Sickle cell disease is one of the most common genetic disorders. Sickle cell crises in which irregular and dehydrated cells contribute to blocking of blood vessels are characterised by episodes of pain. Treatment is mainly supportive and symptomatic. In vitro
S Ricci et al.
The Cochrane database of systematic reviews, (2)(2), CD000419-CD000419 (2006-04-21)
Piracetam has neuroprotective and antithrombotic effects which may help to reduce death and disability in people with acute stroke. The objective of this review was to assess the effects of piracetam in acute presumed ischaemic stroke. We searched the Cochrane
Fulvio Gualtieri et al.
Current pharmaceutical design, 8(2), 125-138 (2002-01-29)
Cognition enhancers are drugs able to facilitate attentional abilities and acquisition, storage and retrieval of information, and to attenuate the impairment of cognitive functions associated with head traumas, stroke, age and age-related pathologies. Development of cognition enhancers is still a
G Justus Hofmeyr et al.
The Cochrane database of systematic reviews, 6(6), CD001064-CD001064 (2012-06-15)
Piracetam is thought to promote the metabolism of brain cells when they are hypoxic. It has been used to prevent adverse effects of fetal distress. The objective of this review was to assess the effects of piracetam for suspected fetal
Katarzyna Winnicka et al.
Acta poloniae pharmaceutica, 62(5), 405-409 (2006-02-08)
Piracetam (2-oxo-1-pyrrolidine-acetamide), the most common of the nootropic drugs, is a cyclic derivative of gamma-aminobutyric acid. The treatment with piracetam improves learning, memory, brain metabolism, and capacity. Piracetam has been shown to alter the physical properties of the plasma membrane
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持